news
Optibrium, Imperial College and DNDi to collaborate on drug development
The collaboration will provide MSc students with industry-relevant learning tools and pharma with a new pipeline of candidate compounds.
List view / Grid view
Drug Targets
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
news
Making biological drugs with spider silk protein
Researchers at the Karolinska Institutet in Sweden have managed to synthesise lung surfactant, a drug used in the care of preterm babies, by mimicking the production of spider silk.
news
Scientists to test Zika virus on brain tumours
The research, using tumour cells in the laboratory and in mice, will see if the Zika virus can destroy cancer cells.
news
New targeted approach for epilepsy drug therapies
New research from the University of Liverpool, in collaboration with the Mario Negri Institute in Milan, has identified a protein that could help patients with epilepsy respond more positively to drug therapies.
news
Exscientia to collaborate with Sanofi for EUR250mil multiple-product development
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
news
Oxford Genetics licenses CRISPR technology for biotherapeutic discovery
Licensing agreement will expand Oxford Genetics growing bio-therapeutic discovery, design and development service business.
news
New chlamydia drug targets discovered using CRISPR and stem cells
Scientists have created an innovative technique for studying how chlamydia interacts with the human immune system...
news
Researchers identify potential Zika Virus target
New research provides insights into why infection with Zika virus after birth generally causes only mild symptoms, whereas devastating foetal malformations can develop when infection occurs during pregnancy.
news
Q BioMed and Asdera LLC to develop rare paediatric disorder treatment
Among the more than 60,000 US children who develop autism spectrum disorders (ASD) every year, 20,000 become nonverbal or lose the ability to speak. The numbers are similar in Europe and this nonverbal group will have to rely on assisted living for the rest of their life.
news
BenevolentAI to partner with medical research charity MRC technology
BenevolentAI, a British artificial intelligence company, has partnered with MRC Technology (MRCT), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
article
A new approach to Organ-on-a-Chip
Draper's Joe Charest explains how synthetic organoids can lead to safer drug testing, and why organ-on-a-chip technology is the future of drug discovery...
article
Fast-tracking the approach to drug discovery and development
Mundipharma EDO GmbH's Dr Thomas Mehrling talks through the benefits of streamlining the drug discovery and development process using the EDO model...
article
Assays In-Depth Focus 2017
HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole animal screening assay formats. Horst Flotow, from Hit Discovery Constance, discusses the benefits and practicalities of, and recent progress in, whole animal screening. Madhu Lal-Nag, National Center for Advancing Translational Sciences, and Anton…
webinar
Assessing neurological ion channel therapeutic and liability targets
10 March 2017 | By Charles River
This webinar explores neurological ion channel therapeutic and liability targets, featuring four subtypes of NMDA receptors. We also discuss the rationale and options for assessment of therapeutic compounds on panels of CNS ion channels for evaluating their risk for CNS liabilities...
news
JPND launches €23 million call for neurodegenerative disease research
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are a global health, economic and social emergency.
